Conditions: Rheumatoid Arthritis
Keywords: oral JAK inhibitor clinical trial joint diseases anti-Inflammatory agents rheumatic diseases DMARD Antirheumatic Agents Autoimmune Diseases Immune System Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 264
Healthy volunteers: no

Brief summary:
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).

Detailed description:

Arms:
arm 1: CP 690,550 5 mg BID arm 2: CP 690,550 15 mg BID arm 3: Oral tablets administered at a dose of 30 mg BID for 6 weeks arm 4: Placebo

Interventions: intervention 1: CP-690,550 intervention 2: CP-690,550 intervention 3: CP-690,550 intervention 4: Placebo
Intervention descriptions: intervention 1: Oral tablets administered at a dose of 5 mg BID for 6 weeks intervention 2: Oral tablets administered at a dose of 15 mg BID for 6 weeks intervention 3: 30 mg BID for 6 weeks intervention 4: Placebo tablets

Protocol document: